after joining the study, you start receiving kai-9531 or placebo. the study is randomized, which means the treatment is assigned by chance.

the study is double-blind, which means that you and the study staff do not know whether you are receiving kai-9531 or placebo.

kai-9531 is given as a subcutaneous injection, which means an injection under the skin.

the medicine is given once weekly, meaning one time every week.

the planned study dose for kai-9531 is listed as 00 mg. the source data do not provide a usable active dose amount.

you continue with the assigned injection once weekly during the treatment period.

the treatment period lasts until the end of the study follow-up described in the trial. the source data do not list the full visit schedule or the number of injections.

the study compares kai-9531 with placebo, which is an inactive solution that looks the same as the study medicine but does not contain the active drug.

during the study, your body weight is measured. the main goal is to look at the percent change in body weight from the start of the study to week 76.

your hemoglobin a1c (hba1c) is checked. hba1c is a blood test that shows average blood sugar over the past few months.

other measurements may include waist size, absolute weight, fasting blood glucose (blood sugar after not eating), blood pressure, and blood fats such as triglycerides, hdl-cholesterol, non-hdl-cholesterol, total cholesterol, ldl-cholesterol, and vldl-cholesterol.

other study checks may include insulin levels, questions about eating behavior, and questions about how food thoughts affect you.

the study may also check for treatment-emergent adverse events, which means new or worsening medical problems that appear after treatment starts.

blood tests may also look for antidrug antibodies and neutralizing antibodies, which are immune proteins that can react against the study medicine.

the amount of kai-9531 in your body may also be measured.

the main results are assessed at week 76.

the study checks whether your body weight has changed and whether your hba1c has changed from the start of the study.

the study may also look at whether your weight has gone down by at least 5%, 10%, 15%, 20%, or 25%.

additional comparisons may include changes in waist size, bmi (body mass index, a number based on height and weight), blood sugar, blood pressure, blood fats, and questionnaire results.

the planned study period ends by the stated study end date.

the source data do not provide any further trial stages after the week 76 assessments and do not list any additional steps.